• MSR12 Accounting for the Additional Uncertainty Following Rank-Preserving Structural Failure Time Model (RPSFTM) Crossover Adjustment in Survival Analysis: A Sage Approach

    Dec 1, 2025, 00:00

  • EE526 Impact of Budesonide-Glycopyrronium Formoterol Initiation on Healthcare Resource Utilization and Carbon Emissions in Patients With COPD in Spain: Insights From the ORESTES Study

    Dec 1, 2025, 00:00

  • HTA5 A Cross-Sectional Analysis of Early Access Programs in NICE Health Technology Assessments

    Dec 1, 2025, 00:00

  • EPH132 Identifying Risk Factors Associated With Meningioma: A Systematic Review

    Dec 1, 2025, 00:00

  • P41 Cost-Effectiveness Modeling of CAR-T Cell Therapies in Hematologic Malignancies: Insights From NICE and CDA-AMC Appraisals

    Dec 1, 2025, 00:00

  • SA83 Real-World Utilization Patterns of Corticosteroids in Ulcerative Colitis: Prevalence of Excessive Use in Routine Clinical Practice

    Dec 1, 2025, 00:00

  • MSR153 Natural Language Processing Solution (REALLI) to Evaluate the Limitations of the French National Health Insurance Database (SNDS): Example of HER2+ Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • EE557 Integrating Environmental Sustainability Into Cost-Effectiveness Analysis and Value Demonstration: A Multidimensional Framework

    Dec 1, 2025, 00:00

  • CO235 The Clinical and Economic Impact of the Introduction of Emicizumab as Prophylactic Treatment for Hemophilia A Patients in Greece

    Dec 1, 2025, 00:00

  • HPR128 International Reference Pricing (IRP) Analysis for Original Medicines in Türkiye in 2024

    Dec 1, 2025, 00:00

  • EE359 Economic Burden of COVID-19-Related Hospitalizations in Finland: A 4-year Longitudinal Analysis

    Dec 1, 2025, 00:00

  • HTA171 Health Equity Considerations in Economic Evaluation: Comparative Acceptability and Application Across European HTA Bodies

    Dec 1, 2025, 00:00

  • PCR95 Exploring the Use and Perception of Patient-Reported Outcome Evidence Among Cardiologists and Patients With Heart Failure

    Dec 1, 2025, 00:00

  • RWD137 Prevalence Utilization Patterns and Economic Impact of eGFR and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Real-World Analysis From Greece

    Dec 1, 2025, 00:00

  • HTA53 Beyond Productivity: How Professional Identity Shapes Generative AI Adoption Among Medical Writing Professionals

    Dec 1, 2025, 00:00

  • CO124 Gaps in Cancer Screening Uptake in Ireland: Trends, Barriers and Policy Implications

    Dec 1, 2025, 00:00

  • EE632 Quantifying the Value of Information in Early Stage Health Technology Assessment: Guiding Investment in Evidence Generation

    Dec 1, 2025, 00:00

  • MSR203 Traditional vs. Generative AI: A Rapid Systematic Review Assessing Accuracy and Efficiency of AI in Title/Abstract Screening

    Dec 1, 2025, 00:00

  • SA30 Designing Digital Healthcare Professional Surveys: A Methodological Overview

    Dec 1, 2025, 00:00

  • EE488 Health Economic Analysis of Risk- and Age-Based Pneumococcal Vaccination With PCV21 vs. PCV20 in France

    Dec 1, 2025, 00:00

  • HPR40 Building Risk-Sharing Agreements in Chile: Feasibility and Policy Options

    Dec 1, 2025, 00:00

  • HPR122 Including Decision Uncertainty About the Clinically Minimal Important Differen Shifting From Risk Aversion to Risk Awareness in Drug Reimbursement Processes

    Dec 1, 2025, 00:00

  • EPH157 Length of Stay (LOS) and Associated Healthcare Resource Use (HCRU) for a First Infusion of Axi-cel or Lisocel in Second Line for Large B-cell Lymphoma in Fran Differences Observed From Comprehensive Hospital Databases

    Dec 1, 2025, 00:00

  • HTA363 What Generalized Cost-Effectiveness Analysis (GCEA) Reveals About the Applicability of Foreign Reference Pricing in Medicare Price Negotiation in the US

    Dec 1, 2025, 00:00

  • EE344 Drivers of Inpatient Costs in Oncology Patients Undergoing Major Abdominal Surgery: Evidence from a Middle-Income Country

    Dec 1, 2025, 00:00

  • MSR15 Advancing Target Trial Emulation With Synthetic Data: The Target Trial Optimization Framework

    Dec 1, 2025, 00:00

  • CO144 Improvements in Scalp Outcomes With Roflumilast Foam 0.3% for Psoriasis of the Scalp and Body From the Phase 3 ARRECTOR Trial

    Dec 1, 2025, 00:00

  • HTA152 From GVD to HTA: Preparing for Success in the EU JCA Era With GenAI-Enhanced Efficiency

    Dec 1, 2025, 00:00

  • MSR70 Development and Assessment of a Portability Strategy for Computable Operational Definitions

    Dec 1, 2025, 00:00

  • PCR231 The Impact of Inhaler Technique on the Health Outcomes and Cost Among Adults With Asthma and Chronic Obstructive Pulmonary Disease in Saudi Arabia

    Dec 1, 2025, 00:00

  • HPR102 From Deficit Risk to Surplus Strength: A Revenue-Centered Analysis of Türkiye’s General Health Insurance 2015-2024

    Dec 1, 2025, 00:00

  • EE514 Healthcare Resource Utilization and Economic Burden Among Adults With Alopecia Areata in the United Arab Emirates

    Dec 1, 2025, 00:00

  • HPR133 Longitudinal Trends in Biosimilar Uptake in France 2019-2024: Insights by Dispensing Pathway and Prescribing Origin

    Dec 1, 2025, 00:00

  • SA64 Mapping Disease-Specific Patient-Reported Outcome Measures (PROMs) to EQ-5D Utility Scores: A Systematic Review

    Dec 1, 2025, 00:00

  • PCR4 A Conceptual Framework for Enhancing the Clinical Utility of a Generic Veterinary Health-Related Quality of Life (HRQoL) Tool Vetmetrica™ Through the Addition of a Disease-Specific Module

    Dec 1, 2025, 00:00

  • RWD80 Evolution of Utilization and Costs of Long-Acting Injectable Antipsychotics (LAIs) in Outpatient Care at Lisbon Psychiatric Hospital (March-May 2022 vs. 2025)

    Dec 1, 2025, 00:00

  • EPH165 Monitoring the Burden of Lung Cancer in Germany: Trends in Incidence and Survival Using ZfKD Registry Data 2020-2023

    Dec 1, 2025, 00:00

  • EE507 Healthcare Resource Utilization in Patients With Hidradenitis Suppurativa Using Adelphi Real-World Data From EU5 and US

    Dec 1, 2025, 00:00

  • EPH236 The Health Impact of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab Treatment for High-Risk Early Stage Triple-Negative Breast Cancer (eTNBC) in Türkiye

    Dec 1, 2025, 00:00

  • HTA80 Comparator Misalignment As a Contributor to Negative Reimbursement Decisions for Pharmaceuticals in Sweden

    Dec 1, 2025, 00:00

  • EE119 Burden of Schizophrenia on the Brazilian Public Healthcare System: A Cost and Service Analysis

    Dec 1, 2025, 00:00

  • EE560 Introducing the Parameter Outcome Overview Plot: A New Addition to the Sensitivity Analysis Armory for Economic Models

    Dec 1, 2025, 00:00

  • EE728 The VIS1ON Horizon Scanning Model: Predicting the Evolution of Direct NHS Expenditure for Type 1 Diabetes in Italy up to 2028

    Dec 1, 2025, 00:00

  • SA39 Evaluating the Public Health Impact of Adolescent Meningococcal B (MenB) Vaccination in Fran A Modeling Approach

    Dec 1, 2025, 00:00

  • MT41 The Role of Flexible Cysto-Nephroscope in Enhancing Stone-Free Rates of Percutaneous Nephrolithotomy: A Global Survey

    Dec 1, 2025, 00:00

  • PCR134 Impacts of Patient-Centered Collaboration: Application of a Continuous Engagement Plan Across Multiple Phases of the Insights and Patient Experiences With Cardiovascular Disease (IPEC) Initiative

    Dec 1, 2025, 00:00

  • HSD63 Inequity in Public Healthcare Utilization Among Persons With Disabilities in Bangladesh: A Benefit Incidence Analysis

    Dec 1, 2025, 00:00

  • MSR66 Dealing With Missing Data in Health Economic Studies of Small to Moderate Size: How to Minimize Bias

    Dec 1, 2025, 00:00

  • EE301 Cost-Utility Analysis Of Erdosteine for the Prevention of Exacerbations in Patients With COPD in the Czech Republic

    Dec 1, 2025, 00:00

  • EE747 Value-Based Assessment of Trifluridine Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

    Dec 1, 2025, 00:00

  • PCR60 Development of a Discrete Choice Experiment to Explore Preferences for Self-Sampling in a National UK Cervical Screening Program

    Dec 1, 2025, 00:00

  • EE536 Impact of Maternal Vaccination Strategy on RSV-Related Hospital Burden Among Infants Aged Less Than One Year in Fran A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • EE57 Assessing Public Health and Economic Benefits of Nirsevimab or RSVpreF for Preventing RSV-Related Outcomes in Japanese Infants

    Dec 1, 2025, 00:00

  • CO12 APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes

    Dec 1, 2025, 00:00

  • EPH68 Effect of Education Given to Nursing Students on Their Palliative Care Knowledge and Attitudes

    Dec 1, 2025, 00:00

  • EPH109 Exploring the Impact of Socioeconomic Factors on COVID-19 Vaccine Hesitancy in India: What Can We Learn From the COVID-19 Pandemic? A Scoping Review

    Dec 1, 2025, 00:00

  • RWD190 Use of RWE in HTA Submissions: A Systematic Review of Case Studies Across Three HTA Agencies Reveals Continued Concerns Around Internal Validity and Unmeasured Confounding

    Dec 1, 2025, 00:00

  • HPR14 Access and Evolving Eviden A European HTA Analysis of Innovative Medicines Under Evidence Generation Agreements

    Dec 1, 2025, 00:00

  • HSD112 Transforming Pediatric Type 1 Diabetes Care in Bulgaria Through Structured Patient Journey Analysis

    Dec 1, 2025, 00:00

  • HPR91 Factors Associated With Positive Cost-Effectiveness Judgments in HIRA Drug Reimbursement Decisions: An 8-year Retrospective Review

    Dec 1, 2025, 00:00

  • EE178 Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in Brazil

    Dec 1, 2025, 00:00

  • CO102 Estimating the Mean Time in Treatment-Free Remission for Patients in Early Line CML

    Dec 1, 2025, 00:00

  • EE363 Economic Burden Of Primary Biliary Cholangitis (PBC) in Spain

    Dec 1, 2025, 00:00

  • EE356 Economic Burden in Metastatic Triple-Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • MSR178 Quantifying the Value of Delaying Type 1 Diabetes Progression: A New Cost-Effectiveness Model for Capturing the Value of Delayed Onset

    Dec 1, 2025, 00:00

  • EE419 Estimating Health Utility Decrements Associated With Chronic Disease Outcomes Using MEPS

    Dec 1, 2025, 00:00

  • PCR126 Identifying Patient-Reported Outcome Measures to Capture Patients’ Experiences of Symptoms and Impacts of Acute Myeloid Leukemia (AML)

    Dec 1, 2025, 00:00

  • RWD33 Clinical and Economic Characteristics of eGFR-Mutated NSCLC Patients Treated With TKIs in South Korea: A Retrospective Cross-Sectional Analysis

    Dec 1, 2025, 00:00

  • PCR71 English Translation, Cross-Cultural Adaptation and Validation of the French New Patient-Reported Outcome Measures of the Multiple Sclerosis Autonomy Scale (MSAS)

    Dec 1, 2025, 00:00

  • EE652 Review of CEESP ICERs for Orphan and Nonorphan Treatments in France, 2024-2025

    Dec 1, 2025, 00:00

  • HTA200 Individual Therapy or No Therapy at All: Impact of Patient Individual Therapies As ACT in the German AMNOG Process

    Dec 1, 2025, 00:00

  • EE72 BFM 2009 (Berlin, Frankfurt, Munich) Protocol Cost Analysis for Childhood Acute Lymphoblastic Leukemia (ALL): Preliminary Real-World Data From Brazil/LATAM/LMIC

    Dec 1, 2025, 00:00

  • HTA1 Inefficiencies in Developing UK and Irish HTA Submissions and How to Streamline the Process

    Dec 1, 2025, 00:00

  • HPR19 Alternative Pricing Policies for Multi-Indication Products: A Quantitative Analysis

    Dec 1, 2025, 00:00

  • P12 Work Productivity Loss in Individuals Due to Respiratory Infections: A Questionnaire Survey of Employees in Denmark

    Dec 1, 2025, 00:00

  • RWD189 Use of Big Data to Assess Dyslipidemia Management in Gree Real-World Insights From the National Healthcare Payer

    Dec 1, 2025, 00:00

  • EE269 Cost-Effectiveness of Proton Beam Therapy in the Treatment of Pediatric Medulloblastoma in France

    Dec 1, 2025, 00:00

  • HTA54 Beyond RCTs: The Role of Patient Perspectives and Nontraditional Evidence in HTA Decisions for Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • EE732 To Be or Not to Be Willing to Pay

    Dec 1, 2025, 00:00

  • RWD67 Disproportionality Analysis Of Vedolizumab to Identify a Putative Signal Using Real-World Postmarketing Surveillance Data Reported in the FAERS Database

    Dec 1, 2025, 00:00

  • PCR139 Informing Health System Reform Through Patient Perspectives: Saudi Arabia’s OECD Paris Survey Results

    Dec 1, 2025, 00:00

  • PCR180 Patient Preferences for Type 2 Diabetes Mellitus (T2DM) Treatment: A Systematic Review of Discrete Choice Experiments Studies

    Dec 1, 2025, 00:00

  • CO175 Overall Treatment Landscape of Mucosal Melanoma

    Dec 1, 2025, 00:00

  • HTA243 Navigating HTA and Innovation: Oncologists’ Perspectives on Access to Cancer Therapies in Bulgaria

    Dec 1, 2025, 00:00

  • HPR78 Evaluation of the Implementation Effect of Medical Service Price Reforms: A Case Study of Assisted Reproductive Services in China

    Dec 1, 2025, 00:00

  • RWD60 Development and Implementation of a Dynamic Framework for Assessment and Improvement of Registries’ Data Quality

    Dec 1, 2025, 00:00

  • P6 Potential Modifiers of Cost-Effectiveness Thresholds: Public Perspectives on Prioritization in Healthcare Spending

    Dec 1, 2025, 00:00

  • HPR234 Utilization of Best-Value Medicines for Teriparatide in the Irish Healthcare Setting

    Dec 1, 2025, 00:00

  • MSR218 Validating the Use of Large Language Models to Generate Individual Patient-Level Data for Use in Health Technology Assessment

    Dec 1, 2025, 00:00

  • HTA219 Level of ICER of Health Economic Assessment in France in 2024

    Dec 1, 2025, 00:00

  • P54 Thus SPOKE the TA: Querying NICE Technology Assessments Using Generative AI and RAG

    Dec 1, 2025, 00:00

  • SA65 Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease

    Dec 1, 2025, 00:00

  • HTA261 Organizational Readiness for EU HTA: Early Learnings and Key Considerations for Successful Market Access

    Dec 1, 2025, 00:00

  • MT5 Artificial Intelligence in Health Economics: Opportunities and Challenges for the Future: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE83 Budget Impact Analysis of Early FGFR3 Testing in Metastatic Urothelial Carcinoma: A Finnish Healthcare Perspective

    Dec 1, 2025, 00:00

  • HTA290 Revisiting Rarity: Would Yesterday’s NICE Highly Specialized Technologies Still Qualify Today?

    Dec 1, 2025, 00:00

  • HTA209 Integrating Real-World Evidence Into Oncology HTA Submissions: Recent EU Examples

    Dec 1, 2025, 00:00

  • EPH92 Evaluating Performance of the Experimental EQ-TIPS (V3) for Assessing Infants and Toddlers With Acute Infections: A Mixed-Methods Approach of Cognitive Debriefing and Psychometric Testing

    Dec 1, 2025, 00:00

  • EPH79 Epidemiology and Institutional Treatment Distribution of Patients With Myelofibrosis (MF) in Germany: Insights From a Real-World Evidence Study

    Dec 1, 2025, 00:00

  • EE105 Budget Impact of Azathioprine Metabolite Monitoring in Crohn’s Disease in Algeria

    Dec 1, 2025, 00:00

  • SA25 Cross-Sectional Cohort Design Offers an Efficient Alternative to Prospective Cohort Design in Real-World Studies (RWS)

    Dec 1, 2025, 00:00

  • EPH94 Evaluation of Participation Data in the Context of Cancer Prevention

    Dec 1, 2025, 00:00

  • CO163 Matching-Adjusted Indirect Comparison of Obecabtagene Autoleucel vs. Blinatumomab Inotuzumab Ozogamicin and Ponatinib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia

    Dec 1, 2025, 00:00

  • EE282 Cost-Minimization Analysis and Economic Impact in EGPA: Evidence From MANDARA

    Dec 1, 2025, 00:00

  • RWD114 Late Treatment in Adults With Neurogenic Bowel Dysfunction: A Retrospective Analysis of German Claims Data

    Dec 1, 2025, 00:00

  • EE458 Exploring the Economic Burden Associated With Chronic Obstructive Pulmonary Disease (COPD) Due to Alpha1 Antitrypsin Deficiency (AATD): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE658 Societal and Economic Impact of Immunotherapy for NSCLC Treatment in Bulgaria

    Dec 1, 2025, 00:00

  • HPR112 Health Halo Effect in Supplement Marketing: A Content Analysis of Medical Claims in Community Pharmacies

    Dec 1, 2025, 00:00

  • EE663 Societal Impact Analysis of Introducing Elexacaftor Tezacaftor Ivacaftor (ELX TEZ IVA) in the Management of People With Cystic Fibrosis in Germany: A Paid and Unpaid Work Productivity Approach

    Dec 1, 2025, 00:00

  • HTA350 Use of Data From Phase 3 RCTs in Earlier Lines of Therapy in Support of Noncomparative Evidence From Pivotal Phase 2 Studies

    Dec 1, 2025, 00:00

  • HTA48 Assessment of the Inclusion and Importance of Carer Quality of Life in Global Health Technology Appraisals

    Dec 1, 2025, 00:00

  • EE427 Estimating the Economic Burden of Potential Chikungunya Outbreaks in Southern Europe

    Dec 1, 2025, 00:00

  • HTA34 Analytical Modeling in Economic Evaluations of Obesity Interventions to Inform Health Policy: A Narrative Review

    Dec 1, 2025, 00:00

  • EE19 A Health Economic Evaluation of Daylight: A Digital Treatment for Anxiety in NHS South Yorkshire

    Dec 1, 2025, 00:00

  • PCR243 The SISAQOL-IMI Recommendations on Standardizing the Use of Thresholds for Interpretation of Patient-Reported Outcome Results in Cancer Clinical Trials

    Dec 1, 2025, 00:00

  • SA86 Simulation of the Impact on LDLC Targets and Treatment Cost in High and Very High Cardiovascular Risk Patients of Cost-Based Sequencing of Lipid-Lowering Therapy

    Dec 1, 2025, 00:00

  • HTA42 Artificial Intelligence in Pharmaceutical Payer Decision Making—Assessing Current Use, Strategic Intent, and Infrastructure Readiness

    Dec 1, 2025, 00:00

  • EE377 Economic Evaluation of Cefiderocol for the Treatment of Confirmed MBL-Producing Pathogens in Italy

    Dec 1, 2025, 00:00

  • EPH207 Reported Herpes Zoster Incidence Rates in Immunocompromised Adults Aged 18 Years or Older in England by Ethnicity and Socioeconomic Status: A Large Retrospective Cohort Study

    Dec 1, 2025, 00:00

  • CO243 The Impact on Life Expectancy of Delaying or Avoiding Type 1 Diabetes Using the Metabo-Reno-Cardiovascular Disease Model

    Dec 1, 2025, 00:00

  • HTA88 Confidential Prices in NICE Health Technology Assessment: How Common Are They?

    Dec 1, 2025, 00:00

  • EE79 Budget and Time Impact Analysis of Introducing Subcutaneous Pembrolizumab to Patients From Institution HCP and Patient Perspectives in the United States (US)

    Dec 1, 2025, 00:00

  • CO21 Association Between Invasive Disease-Free Survival/Distant Recurrence-Free Survival and Overall Survival in Patients With Early Stage Triple-Negative Breast Cancer

    Dec 1, 2025, 00:00

  • HTA356 Viable Reimbursement and Financing Models for mHealth Interventions in Sub-Saharan Africa: A Narrative Review

    Dec 1, 2025, 00:00

  • HSD3 Access to Decide on a Generalization: Results From the EVA-Corse Experiment: Efficiency and Clinical Non-Inferiority of a Hybrid Cardiac Rehabilitation Model in Corsica

    Dec 1, 2025, 00:00

  • MSR11 Accounting for Cure Rates Estimated from Progression-Free Survival (PFS) in Long-Term Overall Survival (OS) Projections: A Case Study from Previously Treated Advanced Cancers

    Dec 1, 2025, 00:00

  • PCR47 Collecting Patient Preference Information (PPI) in In-Trial/Exit Interviews: Current Perspectives and Future Considerations

    Dec 1, 2025, 00:00

  • CO60 Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study

    Dec 1, 2025, 00:00

  • EE207 Cost-Effectiveness Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals With Type 1 Diabetes in Sweden: A National Real-World Evidence Perspective

    Dec 1, 2025, 00:00

  • CO82 Economic and Clinical Impact of Advanced Therapies in Moderate-to-Severe Rheumatoid Arthritis in Spain: CIARA Study

    Dec 1, 2025, 00:00

  • MSR208 Uncovering Patient Narratives of Opioid Use and Recovery Using Large Language Models for Topic and Emotion Analysis of Social Media Discussions

    Dec 1, 2025, 00:00

  • PT8 Does Proposed IRP Introduction in the US Align With Current IRP Trends and With Best Practice Guidelines?

    Dec 1, 2025, 00:00

  • EPH147 Inequality in Vaccine Uptake: Lessons Learned From Denmark Analyzing Real-World Data From National Registries

    Dec 1, 2025, 00:00

  • EE143 Comparison of Nonstatin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain

    Dec 1, 2025, 00:00

  • EE157 Cost and Healthcare Resource Utilization Associated With Chronic Inducible Urticaria: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE640 Real-World–Based Cost-Effectiveness of Lipid-Lowering Therapies for ASCVD Patients With High CV Risk in Taiwan

    Dec 1, 2025, 00:00

  • EE723 The Societal Value of Lecanemab for Patients With Early Alzheimer's Disease in Japan

    Dec 1, 2025, 00:00

  • P4 Simulating Sponsor-HTA Conversations: A Multi-Agent GenAI Framework for Reimbursement Processes

    Dec 1, 2025, 00:00

  • MSR193 Synthetic Data Generation Methods Using Artificial Intelligence (AI): A Simple New AI Tool That Generates Synthetic Data Using Generative Adversarial Network (CTGAN), Copula GANs, and Sequential Decision Tree Methods

    Dec 1, 2025, 00:00

  • CO220 Subtyping Atopic Dermatitis Trajectories Using Digital Patient-Reported Outcomes and Machine Learning

    Dec 1, 2025, 00:00

  • EE626 Quantifying the Economic Impact of Flexible Endoscope-Related Procedure Rescheduling in NHS Endoscopy Services: A Retrospective Analysis and Survey-Based Model

    Dec 1, 2025, 00:00

  • HPR86 Exploring Off-Label Drug Coding Trends in French Hospitals: A Descriptive and Stratified Analysis 2020-2024

    Dec 1, 2025, 00:00

  • EE116 Burden of Disease in Hereditary Transthyretin Amyloidosis With Polyneuropathy in Spain

    Dec 1, 2025, 00:00

  • HPR51 Comparison of the Early Access and Postmarket Evaluation Systems in South Korea and Germany’s DIGA

    Dec 1, 2025, 00:00

  • MSR136 Leveraging Generative Artificial Intelligence for the Creation of Global Value Dossiers Through a RAG Pipeline and Multi-Agent Integration

    Dec 1, 2025, 00:00

  • EE328 Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework

    Dec 1, 2025, 00:00

  • CO189 Primary Lateral Sclerosis (PLS): A Targeted Literature Review of Symptoms, Progression, and Outcomes to Inform Evidence Gaps for Rare Neurological Disorders

    Dec 1, 2025, 00:00

  • EE96 Budget Impact Analysis of STRIDE (Tremelimumab + Durvalumab) vs. Atezolizumab + Bevacizumab for Unresectable Hepatocellular Carcinoma: Qatari Payer and Societal Perspectives

    Dec 1, 2025, 00:00

  • HSD32 Describing the Real-World Burden of Demodex Blepharitis: A Multicenter Audit in a UK Public Specialist Eye-Care Setting

    Dec 1, 2025, 00:00

  • MSR159 Optimizing Patient Retention in Non–Site-Based Longitudinal Studies: Tailored Follow-up Strategies for Rare Disease Cohorts

    Dec 1, 2025, 00:00

  • EE192 Cost-Consequence and Clinical Impact of NGS Testing in Advanced Lung Adenocarcinoma: Real-World Evidence From a Portuguese Public Hospital

    Dec 1, 2025, 00:00

  • HPR58 Distributional Cost-Effectiveness Analysis: A Case Study of Obesity

    Dec 1, 2025, 00:00

  • RWD79 Evaluation of Real-World Data Landscape in the United Kingdom: A Scoping Review

    Dec 1, 2025, 00:00

  • CO192 Projected Public Health Benefits of Nirsevimab for RSV Prevention in Infants in Greece

    Dec 1, 2025, 00:00

  • HTA117 Dutch Cost Implications of Faricimab in Neovascular Age-Related Macular Degeneration: A Systematic Review of Treatment Interval and Injection Frequency

    Dec 1, 2025, 00:00

  • MSR3 A Generalizable Discrete Event Simulation Framework to Assess Clinical and Economic Impact of Prescription Protocol Revisions

    Dec 1, 2025, 00:00

  • HTA127 Equality Considerations in NICE Guidance of Medical Devices Digital and Diagnostic Technologies and Interventional Procedures

    Dec 1, 2025, 00:00

  • PCR151 Mapping the Evidence on Interrelationships Between Cancer Stage Financial Toxicity (FT) and Health-Related Quality of Life (HRQoL)

    Dec 1, 2025, 00:00

  • MSR143 Matching Adjusted Indirect Comparison of Asciminib vs. Flumatinib as First-Line Treatment for Chronic Myeloid Leukemia in China

    Dec 1, 2025, 00:00

  • EPH174 Out-of-Work Transitions in the European Population With Noncommunicable Diseases

    Dec 1, 2025, 00:00

  • HSD47 Evaluating the Validity of Immunotherapy in Retreatment and Rechallenge Strategies for Oncology Patients

    Dec 1, 2025, 00:00

  • MSR119 How Can the Threshold Method Guide the Choice of Treatments? Illustration in French Patients With Hemophilia A or B

    Dec 1, 2025, 00:00

  • HTA227 Mapping Writer-AI Conversations for HTA: Preliminary Analysis of 7009 Messages

    Dec 1, 2025, 00:00

  • CO200 Real-World Pharmacovigilance of Metoprolol: A Disproportionality Analysis of Adverse Events Using US FDA Adverse Event Reporting System (FAERS) and Bioinformatics

    Dec 1, 2025, 00:00

  • EE212 Cost-Effectiveness Analysis of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for Patients With High-Risk Early Stage Triple-Negative Breast Cancer in Chile

    Dec 1, 2025, 00:00

  • PCR251 Treatment Preferences in Adults With Chronic Spontaneous Urticaria Symptomatic on H1-Antihistamines in the Netherlands: Insights From CHOICE-CSU 2 Study

    Dec 1, 2025, 00:00

  • HPR126 Integrating Guidance Through a Whole Life-Cycle Approach: Wouldn’t It Be NICE?

    Dec 1, 2025, 00:00

  • PCR259 Using Social Media Listening to Understand Oncology-Specific Patient Experiences: A Comparison of Pharmaceutical Industry-Funded vs. Nonpharmaceutical Industry-Funded Studies

    Dec 1, 2025, 00:00

  • PT2 Frequency and Impact of External Comparator Arms in Oncology HTA Assessments With Single-Arm Trials in the UK, France, and Germany From 2014 to 2024

    Dec 1, 2025, 00:00

  • MSR19 AI Models for Predicting Clinical Trial Success: Capabilities and Risks of Pattern-Driven Approaches

    Dec 1, 2025, 00:00

  • PCR236 The Mediating Role of Insomnia in the Relationship Between Disease Severity and Mental Health Quality of Life and Productivity in Atopic Dermatitis

    Dec 1, 2025, 00:00

  • HSD20 Care Dependency and Sick Leave Patterns in Early Alzheimer's Disease: A Retrospective Claims Data Analysis in Germany

    Dec 1, 2025, 00:00

  • PT11 High Entry Costs Slower Growth: A Nationwide Register Study on Newly Reimbursed Biologic Medicines in Finland 2011-2021

    Dec 1, 2025, 00:00

  • EE500 Healthcare Costs in People With Type 2 Diabetes Remaining on or Escalating From Basal-Supported Oral Therapy: A 5-Year German Statutory Health Insurance Claims Data Analysis

    Dec 1, 2025, 00:00

  • PCR217 Social Determinants of Health Affecting Response to Opioid Addiction Treatment

    Dec 1, 2025, 00:00

  • HTA270 Potential Implications of EU Joint Clinical Assessment (JCA) for the UK Affiliate of a Global Pharmaceutical Company

    Dec 1, 2025, 00:00

  • HSD1 A Case Study Demonstrating the Utility of the High-Tech Hub Electronic Prescribing Facility to Identify Off-Label Prescribing

    Dec 1, 2025, 00:00

  • HTA132 Evaluating High-Cost Gene Therapies for Noncancer Conditions: Insights From NICE's Standard Appraisal Process

    Dec 1, 2025, 00:00

  • EE492 Health Economic Evaluation Model for Prostate Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • HPR114 How Health Policy Influences HTA Outcomes: Comparative Insights From Ukraine, Moldova, and Bulgaria

    Dec 1, 2025, 00:00

  • EPH152 Ischemic Stroke in Europe: Incidence Trends Over Three Decades (1991-2021)

    Dec 1, 2025, 00:00

  • RWD150 Real-World Characterization of Urticaria Subtypes in Brazil: A TriNetX-Based Analysis of Demographics, Comorbidities, Treatments, and Laboratory Markers

    Dec 1, 2025, 00:00

  • EE624 Quantification of Life-Cycle Value Using Early Modeling to Support RD and Strategy Decisions: A Case Study of a Polymeric Heart Valve

    Dec 1, 2025, 00:00

  • EE115 Budgetary Impact of Generalized Pustular Psoriasis (GPP) in the Brazilian Private Healthcare System: A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • HPR226 Uncertainties in Regulatory Benefit-Risk Decision Making for Innovative Anticancer Therapies: Preliminary Results From a 2011-2024 Review of Extensions of Indications

    Dec 1, 2025, 00:00

  • EE494 Health Economic Modeling Approaches for Assessing the Value of a Clostridioides Difficile Vaccination Program: A Literature Review

    Dec 1, 2025, 00:00

  • PCR156 Measuring the Disease Burden and Quality of Life From the Schizophrenia Caregivers’ Perspective

    Dec 1, 2025, 00:00

  • PCR57 Describing the Burden of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) on Patients and Their Caregivers: A Real-World Survey in Europe, the United States, and Japan

    Dec 1, 2025, 00:00

  • HTA20 Activity of the French Economic and Public Health Evaluation Committee (CEESP): Retrospective of 10 Years of Economic Assessment on Health Products

    Dec 1, 2025, 00:00

  • MSR132 Instrumental Variable Treatment Effects Estimation: A Simulation Comparison of Instrumental Variables and OLS Approaches

    Dec 1, 2025, 00:00

  • EPH3 A Critical Review of the Screening Criteria Ratings and Recommendations by the UK National Screening Committee (NSC) for 30 Adult Conditions

    Dec 1, 2025, 00:00

  • CO25 Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-Week Mirikizumab Induction: Real-World Data From IBD BioResource

    Dec 1, 2025, 00:00

  • HSD60 Humanistic and Financial Burden Experienced by Nonprofessional Care Partners of Patients With Mild Cognitive Impairment and Dementia Due to Alzheimer’s Disease: Results From a Real-World Survey in Spain

    Dec 1, 2025, 00:00

  • RWD55 Deep Real-World Analysis of Patients With Myelofibrosis Using Natural Language Processing and Machine Learning: A Methods Description

    Dec 1, 2025, 00:00

  • MSR96 Evaluating the Reliability of Value of Information Methods: A Simulation-Based Comparison

    Dec 1, 2025, 00:00

  • SA80 Real-World Cancer Treatments for Common Solid Tumors in China: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • PCR11 A Systematic Review of Trends From Migraine Preference Studies

    Dec 1, 2025, 00:00

  • CO59 Comparative Efficacy Safety and Discontinuation of Inhaled Levodopa for Patients With Parkinson’s Disease: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • HTA360 What Counts? Exploring Stakeholder Perspectives on the Value of Guiding Criteria for Prioritizing Public Funding of Health Technologies

    Dec 1, 2025, 00:00

  • EPH227 The Association Between Generalized Anxiety Disorder Symptom Severity and Comorbid Health Conditions Among the US General Adult Population

    Dec 1, 2025, 00:00

  • HTA228 Market Access 2030: AI-Driven Dossier Transformation and Therapeutic Value Communication Across Global Health Systems

    Dec 1, 2025, 00:00

  • EE135 Comparative Analysis of Pan-European Severity Assessment Methods and Their Uncertainty in Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • MSR53 Can Generative Artificial Intelligence (GenAI) Be Leveraged to Automate Scoping Searches of Systematic Literature Reviews (SLRs)?

    Dec 1, 2025, 00:00

  • MSR206 Transporting Treatment Effects for Survival Outcomes Under Informative Censoring: A Simulation Study Using Summary-Level Data in the Target Population

    Dec 1, 2025, 00:00

  • SA61 Leveraging AI for Evidence Synthesis: Assessing the Accuracy and Efficiency of AI-Supported Data Extraction and Reporting

    Dec 1, 2025, 00:00

  • HSD13 Barriers and Enablers in Health System Redesign

    Dec 1, 2025, 00:00

  • EE53 Early Outpatient Follow-up and Reduced Health Care Resource Utilization in Acute Heart Failure in Germany: A Descriptive Analysis

    Dec 1, 2025, 00:00

  • EE68 Assessment of the Cost Utility of Palivizumab for Preventing Severe Respiratory Syncytial Virus (RSV) Infection in Preterm Infants Born 29-35 Weeks' Gestational Age in the Philippines

    Dec 1, 2025, 00:00

  • RWD120 Making Health Data Trustees Sustainable: An Overview of Potential Business and Financing Models

    Dec 1, 2025, 00:00

  • EPH200 Quality of Life of Patients Living With Epilepsy in Hungary

    Dec 1, 2025, 00:00

  • EPH164 Molecular Testing Strategies and Their Impact on Treatment Decision in HR+/HER2- Metastatic Breast Cancer: A Real-World Analysis From German Centers

    Dec 1, 2025, 00:00

  • EE577 Methodological Challenges for the Economic Evaluation of Genomic Newborn Screening: A Scoping Review

    Dec 1, 2025, 00:00

  • HSD88 Physician Perspectives on Unmet Need and Treatment Options Among Patients With Relapsed Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Canada: Findings From Qualitative Interviews

    Dec 1, 2025, 00:00

  • PCR116 Health-Related Quality of Life in Firstline Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review With Focus on the PD-L1 Negative Subgroup

    Dec 1, 2025, 00:00

  • MSR90 Evaluating an Automated AI-Driven Pipeline for Literature Surveillance and Synthesis: A Proof-of-Concept for Health Economics and Outcomes Research (HEOR) Communications

    Dec 1, 2025, 00:00

  • CO8 An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin

    Dec 1, 2025, 00:00

  • CO222 Survival Outcomes in People Living With HIV Who Experienced Progressive Multifocal Leukoencephalopathy Compared to the General Population

    Dec 1, 2025, 00:00

  • EPH49 Comorbidities of Anxiety Disorders in Children and Adolescents in Germany: A Nationwide Representative Claims Data Analysis

    Dec 1, 2025, 00:00

  • HSD119 Understanding Trends and Opinions on More Environmentally Friendly Healthcare: A Clinician Survey

    Dec 1, 2025, 00:00

  • PCR88 Explaining Psychiatric Comorbidities in Patients With Skin Conditions: The Importance of Clinical Characteristics and Patient-Reported Disease Impact

    Dec 1, 2025, 00:00

  • EE128 Clinical and Economic Burden Among Patients Requiring Long-Term Intermittent Catheter Use in England: A Real-World Retrospective Observational Cohort Study

    Dec 1, 2025, 00:00

  • RWD1 A Description of the Incidence and Burden of Hyperkalemia in Irish Hospitals 2022-2024

    Dec 1, 2025, 00:00

  • PCR186 Perspectives of Patients and Healthcare Providers on a Shared Decision-Making Dashboard in Rheumatoid Arthritis Care

    Dec 1, 2025, 00:00

  • EPH159 Mapping of Treatment Patterns and Transfusion Status in Danish and Swedish Myelofibrosis (MF) Patients

    Dec 1, 2025, 00:00

  • EE609 Piloting Structured Expert Elicitation: An Exploratory Case Study of Practical Implementation

    Dec 1, 2025, 00:00

  • SA33 Developmental Rehabilitation in Children With Autism: Utilization and Economic Burden in South Korea

    Dec 1, 2025, 00:00

  • CO74 Dinutuximab Beta vs. Historical Controls in the Maintenance Therapy of Relapsed Neuroblastoma: Unadjusted and Adjusted Indirect Comparison

    Dec 1, 2025, 00:00

  • PCR121 Health-Related Quality of Life of Patients With Epidermolysis Bullosa in Hungary: Results With the EQ-5D-5L and EQ-5D-Y-3L Preference-Based Measurement Tools

    Dec 1, 2025, 00:00

  • CO180 Pillcam COLON 2 for Investigation of the COLON Through Direct Visualization: A Systematic Review

    Dec 1, 2025, 00:00

  • EE370 Economic Evaluation in Alzheimer’s Disease: A Systematic Review

    Dec 1, 2025, 00:00

  • PCR267 What Affects Quality of Life Most in Oral Cancer Therapy? A Pilot Study of Adherence and Side Effects

    Dec 1, 2025, 00:00

  • HTA6 A Decade in Decision Making: Reviewing Trends in STAS by NICE in Different Disease Areas

    Dec 1, 2025, 00:00

  • EE457 Exploring LLMs in the Conceptual and Functional Construction of Health Economic Models: A Case Study on Alzheimer's Diagnostic Cost-Effectiveness Model

    Dec 1, 2025, 00:00

  • HSD117 Trends and Economic Impact of Medication Errors in Public Hospitals of Eastern Region Ghana: A Retrospective Analysis From 2018 to 2024

    Dec 1, 2025, 00:00

  • HTA57 Bridging National and EU HTA Regulation: Policy Responses to the JCA Rollout

    Dec 1, 2025, 00:00

  • EE405 Economics of Improved Time in Range in Type 1 Diabetes Management in Italy, Spain, Greece, and Israel

    Dec 1, 2025, 00:00

  • HPR183 Shortage of Antineoplastics and Supportive Medicines in Armenia

    Dec 1, 2025, 00:00

  • EE393 Economic Evaluations of Medical Interventions for Adult People Living With Obesity: Protocol for a Systematic Literature Review

    Dec 1, 2025, 00:00

  • HPR67 Effect of the Inflation Reduction Act on Drug Innovation

    Dec 1, 2025, 00:00

  • EE394 Economic Evaluations of Medication Safety Interventions in Primary Care: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE9 A Cost-Effectiveness Analysis of Abrocitinib vs. Upadacitinib and Baricitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis

    Dec 1, 2025, 00:00

  • HTA304 Subsequent Treatments and NICE Appraisals for DLBCL: A Review of Committee Discussions

    Dec 1, 2025, 00:00

  • EE279 Cost-Effectiveness of T-DM1 vs. Trastuzumab for Adjuvant Treatment in HER2 Early Breast Cancer (eBC) With Residual Disease in Colombia

    Dec 1, 2025, 00:00

  • EE724 The Socioeconomic Burden of Dengue in Spain

    Dec 1, 2025, 00:00

  • EE36 A Systematic Review of Using Social Return on Investments Within Healthcare Service Evaluations: Methodological Opportunity and Challenges

    Dec 1, 2025, 00:00

  • EE132 Clinical and Economic Perspectives on Influenza and COVID-19 Vaccine Combinations

    Dec 1, 2025, 00:00

  • SA42 Feasibility Assessment of a Real-World Comparator Cohort Using Multiple Qualifying Index Lines of Therapy (LOTs) in Third-Line or Later (3L+) Diffuse Large B-cell Lymphoma (DLBCL)

    Dec 1, 2025, 00:00

  • P16 Beyond PFS and OS: Recovering Pre- and Post-Progression Survival From Survival Curves

    Dec 1, 2025, 00:00

  • HSD70 Mapping Anatomic Pathology Laboratories of Public Hospitals in Gree Units, Infrastructure, Personnel, and Workload Estimation

    Dec 1, 2025, 00:00

  • EE27 A Prevalence-Weighted ICER Approach With Scenario Analyses for HTA Without RCT Evidence

    Dec 1, 2025, 00:00

  • MSR49 Bridging the Survival Extrapolation Gap in Health Economic Models: A Case Study on Spline-Based Survival Analysis Using ML-NMR to Address Complex Hazard Function

    Dec 1, 2025, 00:00

  • EE548 Incorporating Environmental Impact Into Health Economic Evaluations: A Review of Methodological Approaches and Practical Applications

    Dec 1, 2025, 00:00

  • SA63 Lung-Cancer Diagnostic Trajectories: A Nationwide Process-Mining Cluster Analysis of 18,569 French Patients

    Dec 1, 2025, 00:00

  • Impact of Constrained Access to Primary Care on Health-Related Quality of Life

    Dec 1, 2025, 00:00

  • EPH167 Multi-Level Factors Influencing Active Surveillance Initiation Among Elderly Medicare Beneficiaries Newly Diagnosed With Low-Risk and Favorable Intermediate-Risk Prostate Cancer: An Active Comparator New User Retrospective Cohort Stu ...

    Dec 1, 2025, 00:00

  • EPH260 Trends in Epidemiology and Mortality of Patients With Bladder Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2025, 00:00

  • EPH160 Measurement of Functional Outcome Using the Modified Rankin Scale in Patients With Acute Ischemic Stroke

    Dec 1, 2025, 00:00

  • HPR145 Navigating Implementation of the EU HTA Regulation for Medical Devices: Insights From National HTA Bodies Across Europe

    Dec 1, 2025, 00:00

  • PT31 Systemic Solutions Influencing Physicians' Prescription Behavior Leading to Savings in the Reimbursement Budget in European Countries: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EPH90 Estimation of HER2-Negative Metastatic Breast Cancer Population Eligible for Innovative Treatments in France

    Dec 1, 2025, 00:00

  • CO22 Association Between Nonvalvular Atrial Fibrillation Type and Therapeutic Failure in Hospitalized Patients With History of Atrial Fibrillation Admitted to a Stepdown Unit

    Dec 1, 2025, 00:00

  • EPH186 Premature Cancer-Related Morbidity and Mortality in Israel: Years Lived With Disability and Years of Life Lost Productivity Costs

    Dec 1, 2025, 00:00

  • SA41 Factors Associated With the Publication of Real-World Evidence Studies in Lung Cancer by Journal Impact Factor

    Dec 1, 2025, 00:00

  • HSD124 Variations in Screening and Medication Takeup Rates for Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • HTA183 HTA and Regulatory Perspectives on Robustness of Evidence and Management of Uncertainties

    Dec 1, 2025, 00:00

  • HTA346 Understanding the Impact of Equality and Equity Considerations on NICE Highly Specialized Technology (HST) Decision Making

    Dec 1, 2025, 00:00

  • EE565 Lifetime Secondary Healthcare Resource Utilization in Phenylketonuria From Birth to Adulthood in Sweden

    Dec 1, 2025, 00:00

  • RWD181 The Use of Oligometastatic Disease in Routine Radiology Practi A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • HTA73 Challenges in the German AMNOG Procedure: The Need for National PICO Transparency and Optimized Consultation Windows in the Context of EU-HTA

    Dec 1, 2025, 00:00

  • CO218 Semaglutide Weight Outcomes Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Real-World Setting

    Dec 1, 2025, 00:00

  • EE601 Optimizing HER2+ Breast Cancer Treatment Pathways in Italian Oncological Centers

    Dec 1, 2025, 00:00

  • CO139 Impact of Pharmacist-Led Interventions on Health-Related Quality of Life in Diabetic Patients: Assessment Using EQ-5D Domains and Visual Analog Scale

    Dec 1, 2025, 00:00

  • EE496 Healthcare and Economic Burden of Intravenous and Subcutaneous Immunoglobulin Treatment in Three Autoimmune Neuromuscular Diseases: A Bicentric Spanish Experience

    Dec 1, 2025, 00:00

  • SA3 A Scoping Review of Resource Modeling in HTA Using Discrete Event Simulation

    Dec 1, 2025, 00:00

  • CO157 Investigating the Patient-Relevance of Achieving Blood Phe Thresholds in PKU: Results From an Analysis of the OPAL Study

    Dec 1, 2025, 00:00

  • EPH117 Group A Streptococcal Infections—Diagnostic Approaches and Antibiotics Prescriptions in Children and Adolescents in Germany: A Nationwide Representative Claims Data Analysis

    Dec 1, 2025, 00:00

  • MSR2 A Disease Progression Model Comparing Respiratory and Motor Decline in People With Late-Onset Pompe Disease Treated With Cipaglucosidase Alfa Plus Miglustat vs. Alglucosidase Alfa

    Dec 1, 2025, 00:00

  • CO245 The Mirage of Stability: Challenges of Predicting Disease Activity Over Time in Systemic Lupus Erythematosus (SLE)

    Dec 1, 2025, 00:00

  • SA31 Determining the Minimal Important Difference of EQ-5D-5L Utility Values in CIDP Patients Using Data From a Large Clinical Trial

    Dec 1, 2025, 00:00

  • PCR194 Protocol for a Health Preference Study on Digital Health Interventions: Integrating DCE and BWS to Capture Subject, Interaction, System, and Societal Value

    Dec 1, 2025, 00:00

  • CO240 The Impact of Dietary Supplements (Vitamin B12, Vitamin D, Magnesium) on the Quality of Life (QoL) of Users in Edessa, Northern Greece

    Dec 1, 2025, 00:00

  • MSR74 Development of Prioritization Criteria for Implementation and Further Development of HTA Methods: Results From SUSTAIN-HTA

    Dec 1, 2025, 00:00

  • HTA288 Retrospective Analysis of Hungarian HTA Submissions Under the Former National Health Economics Guideline

    Dec 1, 2025, 00:00

  • EE266 Cost-Effectiveness of Perioperative Pembrolizumab for Early Stage Non-Small Cell Lung Cancer (NSCLC) in Greece

    Dec 1, 2025, 00:00

  • HTA7 A Gap Analysis of HTA Methods in Europe: Results From SUSTAIN-HTA

    Dec 1, 2025, 00:00

  • HPR123 Innovation in Off-Patent Competitive Environment: Key Learnings From Successes and Failures

    Dec 1, 2025, 00:00

  • HPR16 Accessibility and Time to Reimbursement of Treatments With Substantial Benefit: A Comparative Analysis Focused on Inequalities Between Different European Countries and Different Tumor Types

    Dec 1, 2025, 00:00

  • CO190 Prognostic Accuracy and Clinical Effectiveness of 68Ga-PSMA-11 PET/CT (ILLUCIX®) Imaging Followed by 177-Lu-PSMA-617 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HPR184 Single-Arm Trials and Reimbursement Decision Making in Europe: A Case Study in Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • EE391 Economic Evaluations of First-Line Non-Small Cell Lung Cancer Therapies: A Systematic Review With Focus on PD-L1 Subgroups

    Dec 1, 2025, 00:00

  • EE714 The Impact of Inflation: A Cost Analysis in the Spanish Pharmaceutical Sector From 2014 to 2023

    Dec 1, 2025, 00:00

  • HTA142 Evolving JCA Perspectives From EU Stakeholders and the Impact on Manufacturers

    Dec 1, 2025, 00:00

  • CO203 Real-World Effectiveness of Systemic Therapies in Adults with KRAS(G12C) Metastatic Colorectal Cancer in Europe: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • PCR215 Shared Decision Making in Inflammatory Bowel Disease: An Observational Study Combining Patient Physician and Observer Perspectives

    Dec 1, 2025, 00:00

  • EPH1 A Comparison of the Potential Public Health Impact of PCV15 and PCV20 in French Infants

    Dec 1, 2025, 00:00

  • EPH93 Evaluating the Potential Health and Economic Impact of V116 vs. PCV20 on Invasive Pneumococcal Disease Among Adults in the United Kingdom

    Dec 1, 2025, 00:00

  • EE291 Costs of Breast Cancer Surgical Care in Newly Diagnosed Patients in 2015 and 2019: A French Nationwide Claims Database Study

    Dec 1, 2025, 00:00

  • EPH56 Delta Price Cost-Effectiveness Analysis of PCV21 vs. PCV20 Use in Adults Aged ≥18 Years in Austria

    Dec 1, 2025, 00:00

  • PCR120 Health-Related Quality of Life of Caregivers of Children and Adolescents With Disease in Korea

    Dec 1, 2025, 00:00

  • EPH83 Epidemiology of Wilson's Disease in Europe: A Literature Review

    Dec 1, 2025, 00:00

  • CO161 Management of Biliary Tract Cancer: A Modified Delphi (Consensus) Survey of UK Clinical Experts

    Dec 1, 2025, 00:00

  • EE309 Cost-Utility Analysis of the AlloMap® Test for the Monitoring of Patients After Heart Transplantation: Economic Evaluation Alongside the CUPIDON Trial

    Dec 1, 2025, 00:00

  • HSD108 The Micro-Meso-Macro (3M) Impact Framework: Capturing Health System Value Across Interacting Levels

    Dec 1, 2025, 00:00

  • HTA29 AI in Evidence Synthesis: Have We Reached the Promised Land or Are We Still Wandering the Desert?

    Dec 1, 2025, 00:00

  • HTA264 Patient Access Delays for Subsequent High-Value Indications of Multi-Indication Treatments: An Assessment of Health Technology Assessment Decision Making

    Dec 1, 2025, 00:00

  • OP13 Knowledge of Natural Contraception and Its Effect on the Relationship: Mobile Application

    Dec 1, 2025, 00:00

  • EE387 Economic Evaluation of Tarlatamab as Second-Line Therapy for Metastatic Small-Cell Lung Cancer: A United States Perspective

    Dec 1, 2025, 00:00

  • EPH179 Pharmacovigilance of Cannabis-Based Products in Brazil

    Dec 1, 2025, 00:00

  • EE666 Socioeconomic Burden (SOB) of Multiple Sclerosis (MS) in Latin America (LATAM): Trends and Projections 2017-2032

    Dec 1, 2025, 00:00

  • EE16 A Cost-Utility Analysis of Ferric Derisomaltose vs. Ferric Carboxymaltose in Patients with Iron Deficiency Anemia and Inflammatory Bowel Disease in the United Kingdom: Accounting for Difference in Fracture Risk

    Dec 1, 2025, 00:00

  • SA27 Data Reliability in Retrospective Chart Review Studies: Results and Considerations From a Novel Data Review Methodology

    Dec 1, 2025, 00:00

  • RWD86 From Clinic to Cohort: The VOICE Vitiligo Registry and Bioresource as a Blueprint for High-Fidelity Specialist Registries

    Dec 1, 2025, 00:00

  • RWD63 Development of an LLM-Based Computable Phenotype for Pediatric Lymphoma Subtypes Using Structured and Unstructured Electronic Medical Record Data

    Dec 1, 2025, 00:00

  • Poor Patient Care Outcomes and Nurse Job Outcomes Associated With Unfavorable Intensive Care Unit and Emergency Department Nurse Work Environments: Implications for Critical Care Medicine

    Dec 1, 2025, 00:00

  • HTA316 The Greek Drug Price Negotiation Committee and Its Contribution in Optimizing the Management of EOPYY's Pharmaceutical Budget

    Dec 1, 2025, 00:00

  • EPH205 Real-World Treatment Patterns of Trofinetide in Rett Syndrome: Analysis of Medical Pharmacy-Linked Claims Database in the United States

    Dec 1, 2025, 00:00

  • MSR182 Rescaled Tariff Regression for EQ-5D-5L Health State Valuation: An Equivalent Alternative to the Nonparametric Crosswalk

    Dec 1, 2025, 00:00

  • P52 Evolution of Risk-Sharing Agreements for Orphan Drugs 2015-2024

    Dec 1, 2025, 00:00

  • EE214 Cost-Effectiveness Analysis of Oteseconazole vs. Fluconazole for Patients With Severe Vulvovaginal Candidiasis in China

    Dec 1, 2025, 00:00

  • RWD185 Trends and Disparities in Prostate Cancer Incidence Prevalence and Survival: A SEER Analysis 2000-2022

    Dec 1, 2025, 00:00

  • EE686 The Broader Economics of Chronic Spontaneous Urticaria (CSU) in Japan: Assessing Societal and Fiscal Benefits of Novel Therapies

    Dec 1, 2025, 00:00

  • EE292 Cost-Savings Analysis of Fitusiran Prophylaxis: Reducing Breakthrough Bleeding Treatment Expenditure in the Kingdom of Saudi Arabia

    Dec 1, 2025, 00:00

  • PCR240 The Relevance of Core Outcome Sets to Improving Healthcare Decision Making

    Dec 1, 2025, 00:00

  • MSR95 Evaluating the Performance of a Supervised Artificial Intelligence Model in Screening Abstracts for Oncology-Focused Targeted Literature Reviews

    Dec 1, 2025, 00:00

  • HPR130 Investigation of Patient Satisfaction With Home Nursing Care Among Recipients

    Dec 1, 2025, 00:00

  • HTA343 US Payer Assessment of the Utility and Impact of Value Dossiers on Decision Making

    Dec 1, 2025, 00:00

  • MSR68 Demonstrating the Importance of Modeling Rapid Cancer Progression in Screening Evaluations

    Dec 1, 2025, 00:00

  • EE106 Budget Impact of Implementing a Case-Finding Program in UK Patients at High Risk for COPD to Explore Cost Savings Due to Earlier Diagnosis

    Dec 1, 2025, 00:00

  • HTA168 Harmonization or Hindrance? A Strategic Analysis of Divergent National Requirements Under the EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • HTA75 Clinical Benefit vs. Reimbursement Decisions: Examining Misalignments Between ESMO-MCBS and HTA Outcomes in Oncology

    Dec 1, 2025, 00:00

  • EE445 Evaluating the Impact of Subsequent Anticancer Therapy Use on Life-Year and QALY Estimates in Late-Line Metastatic Colorectal Cancer: A Health Economic Analysis of FRESCO-2

    Dec 1, 2025, 00:00

  • EPH99 Examining Knowledge Regarding Needlestick Injuries Among Students in Higher Healthcare Education

    Dec 1, 2025, 00:00

  • RWD18 Archival Sample Testing for Real-World Insights: Innovative Approaches to Enriching Retrospective Studies With Biomarker Data

    Dec 1, 2025, 00:00

  • PCR228 The Economic Case for Gender Equity: How Closing the Women’s Health Gap Benefits Healthcare Systems and Economies

    Dec 1, 2025, 00:00

  • HPR56 Disparities in Access to Gene Therapy in the European Union: Ethical and Regulatory Challenges

    Dec 1, 2025, 00:00

  • MT47 Variation in Revisions and Complications After Proximal Femoral Fracture Fixation—Association With Provider Characteristics

    Dec 1, 2025, 00:00

  • PCR19 Are We Measuring What Matters in Postpartum Depression Trials?

    Dec 1, 2025, 00:00

  • PCR213 Sex Differences in Patients With Chronic Hand Eczema (CHE): Disease Manifestations and Quality of Life (QoL) Results From a Cross-Sectional Multinational Study

    Dec 1, 2025, 00:00

  • EE668 Spain Leveling Up: A Comparison of Spain’s New National Health Economic Evaluation Guideline With Those of England, France, Germany, Italy, Portugal, Sweden, Ireland, Canada, Australia, and Japan

    Dec 1, 2025, 00:00

  • EE205 Cost-Effectiveness Analysis of Inhaled Levodopa for Managing OFF Episodes in Patients With Parkinson’s Disease

    Dec 1, 2025, 00:00

  • EPH97 Evolution and Geographical Patterns of the Portuguese Newborn Screening Program in the Last 10 Years

    Dec 1, 2025, 00:00

  • MSR116 Give Us the Tools and We Will Finish the Job: How Accurate Is AI for Study Selection in Systematic Reviews?

    Dec 1, 2025, 00:00

  • EE333 Direct Medical Costs of Home-Based Respiratory Support and Oxygen Therapy for Patients With Chronic Respiratory Failure

    Dec 1, 2025, 00:00

  • EPH279 Years of Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Ukraine and in Kiev City, Lviv, and Cherkasy Regions

    Dec 1, 2025, 00:00

  • SA24 Cost Variation Across Lung-Cancer Diagnostic-Pathway Clusters: A Nationwide Real-World Analysis of 18,569 French Patients

    Dec 1, 2025, 00:00

  • CO92 Efficacy and Safety of Inhaled Levofloxacin vs. Other Inhaled Antibiotics in the Treatment of Adults With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection: An Updated Network Meta-Analysis

    Dec 1, 2025, 00:00

  • PCR112 Health-Related Quality of Life (HRQoL) and Its Associated Factors among Chinese Gout Patients: Baseline Findings From a Survey Study

    Dec 1, 2025, 00:00

  • HTA166 Guidance for Real-World Evidence Generation for the Joint Clinical Assessment Process and Its Implications for Country-Specific HTA Body Acceptability

    Dec 1, 2025, 00:00

  • OP24 Turning SAP Feedback into HTA-Ready Action: A Semi-Automated Approach for RWD Studies

    Dec 1, 2025, 00:00

  • MSR7 A New Regulatory-Grade Chronic Disease Cohort Simulator: Leveraging the Large, Deep, and Long Constances Cohort Linked and Matched to the SNDS in France

    Dec 1, 2025, 00:00

  • MT36 Quantifying the Impact of Data Digital and AI on Health Systems

    Dec 1, 2025, 00:00

  • EE167 Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model

    Dec 1, 2025, 00:00

  • EE77 Bridging the Gap: Why Cost-Effectiveness Analyses of Congenital Heart Interventions Are Critical for Person-Centered Value-Based Care

    Dec 1, 2025, 00:00

  • EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status

    Dec 1, 2025, 00:00

  • EE474 First-Trimester Screening for Preterm Pre-Eclampsia in the United Kingdom: A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • HTA39 Are We SEEing It Yet? The Use of Structured Expert Elicitation Protocols for Decision Making

    Dec 1, 2025, 00:00

  • EE633 Real-World Cost of Automated Red Blood Cell Exchange for Sickle Cell Disease in Kenya: A Cost-Reimbursement Gap Analysis From a Public Sector Perspective

    Dec 1, 2025, 00:00

  • MSR20 AI Powered SQL for Real-World Data: From Questions to Insights

    Dec 1, 2025, 00:00

  • EE444 Evaluating the Impact of Different Payment Models on the Cost-Effectiveness and Budget Impact of Cell and Gene Therapies: Eladocagene Exuparvovec As a Case Study

    Dec 1, 2025, 00:00

  • EPH32 Budget Impact of an Organized Screening Program for Chronic Kidney Disease in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • HTA79 Comparative Clinical Effectiveness in Skin Cancer: Lessons From HTA Decision Making in EU4, UK, and Australia

    Dec 1, 2025, 00:00

  • PT16 Patients’ Advocacy Groups in Italy: An Updated Perspective on Activities and Future Directions

    Dec 1, 2025, 00:00

  • EE562 Is Less More? Aggregating Health States in State Transition Models

    Dec 1, 2025, 00:00

  • EPH62 Diabetes Trends in France (2021-2023): A Descriptive Study Based on the THIN Database

    Dec 1, 2025, 00:00

  • HTA126 Environmental Sustainability in HTA: To What Extent Are HTA Bodies Considering Environmental Considerations in Their Decision Making?

    Dec 1, 2025, 00:00

  • PCR135 Improving Patient Involvement in Cancer Clinical Trials: Development of Plain Language Checklists Within the SISAQOL-IMI Initiative

    Dec 1, 2025, 00:00

  • EE534 Impact of Inclusion of Drug Adherence on Cost-Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Disease (ASCVD) Patients

    Dec 1, 2025, 00:00

  • HTA280 Reassessment of Orphan Drugs in Germany After Exceeding the Annual Sales Limit of €30 Million: Impact on the Reimbursement Price and Key Influencing Factors

    Dec 1, 2025, 00:00

  • RWD148 Real-World Associations Between Smoking Status and Genetic Driver Mutations in Metastatic Lung Cancer in US Community Oncology

    Dec 1, 2025, 00:00

  • HTA240 National Implementation of the EU HTA Regulation: Progress and Strategic Developments Across Member States

    Dec 1, 2025, 00:00

  • HPR219 Timing Matters: Missed Opportunity to Prevent RSV Cases in Older Adults in Germany: A Markov Model Analysis

    Dec 1, 2025, 00:00

  • EE310 Cost-Utility Analysis of the BCIS Conveyance Algorithm for Out-of-Hospital Cardiac Arrest Patients

    Dec 1, 2025, 00:00

  • CO57 Comparative Efficacy of First-Line (1L) Therapies for Patients With Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC): An Updated Systematic Literature Review (SLR) and Bayesian Network Meta-Analys ...

    Dec 1, 2025, 00:00

  • EPH185 Predictors of Effectiveness of Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis

    Dec 1, 2025, 00:00

  • HTA25 Advancing a Greener Ecosystem in Health Technology Assessment: A Review of Environmental Integration as an Additional Value Driver

    Dec 1, 2025, 00:00

  • HTA321 The Interim Acceptance and Ultraorphan Pathways in Scotland: An Update

    Dec 1, 2025, 00:00

  • HSD107 The Evolving Role of Pharmacists as Vaccinators in New Zealand and Denmark

    Dec 1, 2025, 00:00

  • CO108 Evaluating the Impact of Censoring on Progression-Free Survival Comparisons of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

    Dec 1, 2025, 00:00

  • HSD50 Examination of Muscle Activity Among Aesthetic Sports Athletes

    Dec 1, 2025, 00:00

  • MSR37 Artificial Intelligence-Powered Literature Reviews (AILRs): Streamlining Joint Clinical Assessment (JCA) Dossier Preparation for the Next Generation of Pharmaceutical Submissions

    Dec 1, 2025, 00:00

  • MT43 Unlocking Value Early: Insights Into NICE’s Early Value Assessments and Evidence-Generation Plans for Medical Technologies

    Dec 1, 2025, 00:00

  • EPH53 Cost-Effectiveness Analysis of the 13-Valent Pneumococcal Conjugate Vaccine Compared With Higher-Valent Alternatives in the Pediatric Population of Paraguay

    Dec 1, 2025, 00:00

  • EPH125 High All-Cause Hospitalization Among Those With Recurrent ASCVD Event: Evidence From a Large-Scale Real-World Database

    Dec 1, 2025, 00:00

  • EE431 Evaluating Cost-Consequences and Digital Transformation Through Concentric Consent: An Impact Assessment at Oxford University Hospitals NHS Foundation Trust

    Dec 1, 2025, 00:00

  • EPH50 Comparative Epidemiological Burden of Osteoarthritis in Eastern Central and Western Europe Based on the Global Burden of Disease Study 2021

    Dec 1, 2025, 00:00

  • SA53 Impact of the Severity of Disease-Related Malnutrition on Healthcare Resource Utilization in Pediatric Patients 1 Year and Older

    Dec 1, 2025, 00:00

  • Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Dec 1, 2025, 00:00

  • EE637 Real-World Healthcare Resource Utilization and Costs by Glycemic Control in People With Type 2 Diabetes: An Observational Population-based Register Study in Sweden

    Dec 1, 2025, 00:00

  • PCR51 Concordance Between Patient and Physician Reporting of Symptoms for Metastatic Urothelial Cancer in Europe: A Real-World Survey

    Dec 1, 2025, 00:00

  • SA32 Developing Best Practice for Using Automation Tools in Literature Reviews

    Dec 1, 2025, 00:00

  • EE641 Reducing External Plasma Dependency: Impact for the Portuguese National Health Service

    Dec 1, 2025, 00:00

  • RWD69 Economic and Clinical Insights Into Oral Nutritional Supplementation in Oncology: A Brazilian Real-World Study

    Dec 1, 2025, 00:00

  • EE436 Evaluating the Cost-Effectiveness of Adjuvanted Influenza Vaccine in the Older Adult Population in the Netherlands

    Dec 1, 2025, 00:00

  • EE360 Economic Burden of Gaucher Disease: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • CO179 Pharmacist-Led Education Improves Inhaler Satisfaction Adherence and Asthma Control in Asthma Patients

    Dec 1, 2025, 00:00

  • EE713 The Impact of Delaying Access to Innovative Therapies in Emerging Markets for Chronic Lymphocytic Leukemia: A Modeling Study

    Dec 1, 2025, 00:00

  • EE236 Cost-Effectiveness of Artificial Intelligence Interventions for Musculoskeletal Disorders: Systematic Review

    Dec 1, 2025, 00:00

  • RWD129 Occupational Disease Claims and Payments in Indonesia: Insights From Administrative Data 2018-2022

    Dec 1, 2025, 00:00

  • OP8 Frameworks for the Use of AI Within HEOR: A Targeted Literature Review and Thematic Analysis

    Dec 1, 2025, 00:00

  • HTA74 Clinical and Economic Factors Underlying QALY Weights and Severity Modifiers in NICE Health Technology Evaluations: An Analysis of Recent Appraisals

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6 (current)
  • 7
  • 8
  • 9
  • 10
  • »